Who succeeded Dr. Paul Cox at Neurocept and why did he leave the role?

1. What the sources say about Paul Alan Cox’s roles and departures

Paul Alan Cox is repeatedly described in organizational bios and news items as executive director of Brain Chemistry Labs and previously as director of the National Tropical Botanical Garden; one long-form profile in Fortune recounts that Cox’s botanical-director role ended when board chair Doug Kinney “decided that he should move on,” suggesting a board-driven transition at that institution ^{[2] [1] [4]}. None of the supplied sources link Cox to an executive role at a company called Neurocept or document him leaving such a position ^{[4] [1]}.

2. What “Neurocept” appears to be in the available results

One of the retrieved items is a consumer-accusation article that calls “Neurocept” a predatory or scam product, alleging fake celebrity endorsements and no scientific backing; that piece treats Neurocept as a commercial supplement or marketed “miracle” rather than a biotech company with conventional executives — but it is an opinion/review style article, not an organizational press release or regulatory filing ^[5]. The article does not connect Neurocept to Paul Cox or to leadership succession ^[5].

3. Where Paul Cox actually works, per public profiles

Multiple profiles and organizational pages identify Cox as founder or executive director of ethnobotany-focused organizations such as Brain Chemistry Labs and as a former director or professor at academic and conservation institutions. Those sources detail his research into L‑serine and neurodegenerative disease diagnostics and treatments, and describe his move away from the National Tropical Botanical Garden as driven by the garden’s board ^{[1] [2] [4] [6]}.

4. Why the specific question about “succession at Neurocept” cannot be answered from these sources

The supplied material contains no announcement, filing, press release, obituary, board minute, or news report that names a successor to Cox at an entity called Neurocept, nor any explanation of Cox resigning or being removed from a Neurocept role. Therefore any statement identifying a successor or the reasons for departure would be outside the available reporting (available sources do not mention a Neurocept leadership change) ^{[1] [5] [2]}.

5. Two plausible explanations — and their evidentiary status

Based on the material: (A) It is possible that Cox never held a formal leadership position at an entity named Neurocept; his known executive title in recent materials is with Brain Chemistry Labs ^{[1] [6]}. (B) Alternatively, if there was a separate company called Neurocept with a leadership change, that event is not captured in the provided results. Both ideas are consistent with the sources but only (A) is directly supported by the supplied profiles ^{[1] [6]}; (B) is a gap in the dataset (available sources do not mention a Neurocept leadership change) ^[5].

6. How to get a definitive answer

To resolve this: check Neurocept’s own corporate filings, press releases, or archived versions of its leadership page; search news wire services and SEC/Companies House records for executive changes; or contact Brain Chemistry Labs and Neurocept directly for confirmation. None of those primary-doc avenues are present in the supplied results, so they are the logical next steps (available sources do not include Neurocept corporate records or press releases) ^{[1] [5]}.

Limitations and competing viewpoints: the Fortune and organizational bios clearly document Cox’s departures and roles in other institutions ^{[4] [2]}. The consumer-review piece frames Neurocept as a scam — if you are investigating a claimed connection between Cox and Neurocept, note that the review’s agenda is consumer protection and is not a substitute for primary corporate records ^[5].